MONECO Advisors LLC bought a new stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,592 shares of the company’s stock, valued at approximately $202,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of AZN. Able Wealth Management LLC bought a new position in AstraZeneca in the 4th quarter worth about $27,000. Pathway Financial Advisers LLC bought a new position in shares of AstraZeneca in the first quarter valued at approximately $29,000. Pin Oak Investment Advisors Inc. grew its stake in AstraZeneca by 468.4% during the fourth quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock valued at $30,000 after acquiring an additional 370 shares in the last quarter. RFP Financial Group LLC increased its holdings in AstraZeneca by 56.3% during the 1st quarter. RFP Financial Group LLC now owns 494 shares of the company’s stock worth $33,000 after acquiring an additional 178 shares during the period. Finally, Northwest Financial Advisors purchased a new stake in AstraZeneca in the 4th quarter worth approximately $34,000. 20.35% of the stock is owned by institutional investors.
AstraZeneca Stock Performance
AstraZeneca stock opened at $84.78 on Tuesday. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $262.86 billion, a PE ratio of 41.56, a P/E/G ratio of 1.36 and a beta of 0.45. The firm has a fifty day simple moving average of $79.47 and a two-hundred day simple moving average of $73.56. AstraZeneca PLC has a twelve month low of $60.47 and a twelve month high of $85.30.
AstraZeneca Cuts Dividend
The business also recently disclosed a Semi-Annual dividend, which will be paid on Monday, September 9th. Shareholders of record on Friday, August 9th will be issued a $0.49 dividend. The ex-dividend date is Friday, August 9th. This represents a yield of 1.8%. AstraZeneca’s dividend payout ratio (DPR) is presently 48.04%.
Wall Street Analysts Forecast Growth
A number of research firms have recently commented on AZN. Citigroup upgraded shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. The Goldman Sachs Group began coverage on shares of AstraZeneca in a research report on Thursday, May 30th. They set a “buy” rating and a $97.00 price target for the company. Argus boosted their price target on shares of AstraZeneca from $80.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, May 30th. Barclays upgraded shares of AstraZeneca to a “strong-buy” rating in a research report on Monday, June 24th. Finally, TD Cowen boosted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $89.75.
Read Our Latest Stock Analysis on AstraZeneca
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.
Read More
- Five stocks we like better than AstraZeneca
- What Are the U.K. Market Holidays? How to Invest and Trade
- Decoding Jackson Hole: The Fed’s Impact on Your Stock Portfolio
- Do ETFs Pay Dividends? What You Need to Know
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- 2 Option Strategies to Maximize Profits in a Bear Market
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.